Tier 4 — mechanistic

Fisetin regulates astrocyte migration and proliferation in vitro

Wang N, Yao F, Li K, Zhang L, Yin G, Du M, Wu B
International Journal of Molecular Medicine 2017 39(4):783-790

Bibliography

PubMed
PMID 28204814
PubMed Central
PMC5360439
DOI
10.3892/ijmm.2017.2890
Funding
Not explicitly stated in the reviewed sections; conducted at the Research Center of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Competing interests
Not stated in the reviewed sections.

Study snapshot

DesignIn vitro scratch-wound migration assay and EdU proliferation assay on primary rat astrocytes treated with fisetin, with flow cytometry cell-cycle analysis and Western blot for FAK, paxillin, cyclin D1, Akt and Erk1/2 phosphorylation.
ModelPrimary rat astrocyte cultures.
SampleIn vitro replicates; exact n not stated in the reviewed abstract.
InterventionFisetin treatment of cultured astrocytes (concentration range not fully specified in reviewed sections).
DurationShort-term in vitro assays (scratch-wound closure and EdU incorporation over standard cell-culture timeframes, typically 24-48 h).
EndpointsAstrocyte migration (scratch-wound assay); Focal adhesion kinase (FAK Tyr576/577) and paxillin (Tyr118) phosphorylation; Cell proliferation (EdU incorporation); Cell cycle distribution (flow cytometry); Cyclin D1 expression; Akt and Erk1/2 phosphorylation; Apoptosis (assessed, no effect found)

What the study showed, in plain terms

After injury to the brain or spinal cord, astrocytes migrate and multiply to form a 'glial scar' that can block nerve regeneration. This study asked whether fisetin — already known to inhibit migration and proliferation in cancer cells — does the same in astrocytes.

Researchers treated cultured rat astrocytes with fisetin and measured how well the cells could move into a wound gap and multiply.

Fisetin reduced astrocyte migration (via lower FAK/paxillin phosphorylation) and slowed proliferation, arresting cells in the G1 phase of the cell cycle and lowering cyclin D1, apparently by reducing Akt and Erk1/2 signalling, without triggering cell death.

Bottom line: a cell-culture-only finding suggesting fisetin might help limit glial scarring after CNS injury by curbing astrocyte migration and proliferation — an interesting mechanistic lead, but with no animal or human data yet to show it works in an actual injury model.

Key findings

Fisetin inhibited astrocyte migration (reducing FAK Tyr576/577 and paxillin Tyr118 phosphorylation) and suppressed proliferation (fewer EdU-positive cells, G1 cell-cycle arrest, reduced cyclin D1) via decreased Akt and Erk1/2 phosphorylation, with no effect on astrocyte apoptosis or p38 MAPK phosphorylation.

What this study can and cannot tell us

In vitro only, using primary rat astrocytes; no animal injury model (e.g., spinal cord injury) or human data to confirm that reduced astrocyte migration/proliferation translates into less glial scarring or better functional recovery in vivo. Fisetin concentration-response and exposure duration are not detailed in the reviewed abstract.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology